Creates provisions relating to cannabis
SB 54 creates a new regulatory framework in Missouri for hemp-derived consumable beverage products and also adds several cannabis-related provisions affecting medical marijuana confidentiality and dispensary operations. The bill defines hemp-derived consumable beverage products, sets product composition limits, requires state licensing and registration, establishes labeling and testing standards, restricts sales to persons 21 and older, and authorizes inspections, enforcement, and seizure of noncompliant products. It also creates a dedicated Hemp Business Fund to support administration of the new program and imposes an excise tax on retail sales of hemp-derived consumable beverage products beginning in 2026.
In addition to the hemp beverage provisions, the bill adds protections for medical marijuana patient and caregiver information by prohibiting state disclosure of certain identifying data to the federal government or unauthorized third parties. It also restricts marijuana dispensary facilities from retaining consumer identifying records unless the consumer consents in writing, and it imposes penalties for violations. The bill further directs the Department of Health and Senior Services and the Division of Alcohol and Tobacco Control to promulgate and enforce rules governing intoxicating cannabinoids, including treating intoxicating cannabinoid products as marijuana for regulatory purposes while excluding hemp and nonintoxicating hemp products from that framework.
The bill would amend chapters 144 and 195, RSMo, by creating new sections that regulate hemp-derived consumable beverage products, establish licensing and registration requirements, authorize state enforcement, and impose a new excise tax. It would also create the Hemp Business Fund, direct tax revenue to veterans' programs, drug abuse prevention and education, and first responder programs, and require new rules on testing, labeling, advertising, and retail sales. Separately, it would add confidentiality protections for medical marijuana records and limit dispensary record retention, affecting state agencies, dispensaries, manufacturers, distributors, retailers, and consumers of hemp and cannabis products.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or partisan division in the available record. Based on the bill text, the measure appears designed to support a regulated hemp beverage market while also tightening oversight of intoxicating cannabinoids and protecting medical marijuana privacy. The overall tone of the legislation is regulatory rather than permissive, with a strong emphasis on age restrictions, product safety, and enforcement.
The main points of contention likely concern how broadly the bill defines and regulates “intoxicating cannabinoids,” because it treats those products as marijuana and subjects them to marijuana-style controls while excluding hemp-derived consumable beverage products. Another likely issue is market access and business structure: the bill requires licensing, registration, testing, and labeling, limits direct-to-consumer shipment, and restricts manufacturers, distributors, and retailers from holding multiple license types or having cross-ownership interests. Privacy provisions for medical marijuana patient data and limits on dispensary record retention may also draw attention from regulators and industry participants, while the new excise tax and enforcement powers could be debated by businesses and consumer advocates.